Clinical trial · Interventional
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse
NCT00546780CI-TRIAL-00005104BMS TIME-1completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib versus bortezomib alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib | Drug | Bortezomib | ALIAS |
| Tanespimycin | Drug | Tanespimycin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm A
- description
- Tanespimycin + Bortezomib
- interventionNames
- Drug: Tanespimycin
- Drug: Bortezomib
- type
- ACTIVE_COMPARATOR
- label
- Arm B
- description
- Bortezomib
- interventionNames
- Drug: Bortezomib
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 6-24 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Good Performance Status * Documented evidence of multiple myeloma * Documented progression of disease after initial response to one line of therapy * Measurable disease (serum M-protein \>.5g/dl or \> 200 mg urinary M protein excretion) Exclusion Criteria: * Prior treatment with a heat shock 90 inhibitor or an investigational proteasome inhibitor * Known active infections of HAV, HBV, HCV, or HIV * Administration of chemotherapy, radiation therapy, or immune therapy within 21 days prior to randomization. * Acute diffuse infiltrate pulmonary disease or pericardial dise
References
Publications (0)
Data not yet available
No reference posted for this study.